Finding the best timing for stem cell transplants in leukemia patients
Official title: Optimizing treatment decision by accounting for longitudinal biomarker trajectories and competing risks of each individual
Funded at University of Tx Md Anderson Can Ctr · NIH-11077755 · Data updated 2026-11-12
This study is looking at how to better time stem cell transplants for people with chronic myeloid leukemia (CML) by analyzing their health data over time, so that patients can get personalized treatment advice that weighs the benefits and risks.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | May 12, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $370,701 |
| NIH project number | 5R01CA272806-03 |
| Project ID | NIH-11077755 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic myeloid leukemia who are considering treatment options, particularly stem cell transplants.
✕Less likely to help
Patients with other types of leukemia or those who are not candidates for stem cell transplants may not benefit from this research.
What this research studies
This research aims to develop advanced statistical methods to evaluate treatment strategies for patients with chronic myeloid leukemia (CML) by analyzing their biomarker data over time. The focus is on determining the optimal timing for stem cell transplants, which can cure leukemia but come with significant risks. By using comprehensive models, the research seeks to provide personalized treatment recommendations based on individual disease progression, helping to balance the benefits and risks of different treatment options. This approach is particularly important as randomized controlled trials are not feasible for this type of decision-making.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment plans for leukemia patients, potentially improving survival rates and quality of life.
How similar studies have gone: While the specific statistical methods being developed are novel, similar approaches in personalized medicine have shown promise in optimizing treatment strategies for various conditions.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Huang, Xuelin — University of Tx Md Anderson Can Ctr
- Study coordinator: Huang, Xuelin
Related research
Other NIH-funded projects on the same topics.
-
HIV-related cervical cancer screening and care in LMICs (AVANÇO HAMRC)
A multi-country effort to build sustainable research infrastructure and low-cost cervical cancer screening and treatment methods for women living with HIV in Brazil and Mozambique.
-
HIV-associated cervical cancer care infrastructure in LMICs
A program to build sustainable research infrastructure and bring low-cost cervical cancer screening, diagnosis, and treatment to women with HIV in Brazil and Mozambique.
-
HIV-associated cervical cancer screening and care network in LMICs
A multinational program aims to build affordable, practical cervical cancer screening, diagnosis, and treatment methods for women living with HIV in Brazil and Mozambique.
-
Mapping HIV-like SIV Reservoirs in the Brain with Advanced PET Imaging
This project develops brain-targeted imaging probes to map SIV reservoirs in the central nervous system of infected macaques, aiming to improve our understanding of how HIV-like viruses hide in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Germline clues to skin-related immune side effects from cancer immunotherapy
This grant looks for genetic clues in people treated with immune checkpoint inhibitors to understand why some develop skin-related immune side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.